Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model

Health Economics Review

Volumn 2, Issue 1, 2012, Pages 1-10

  Schobert, Deniz ^a   Remy, Vanessa ^b   Schoeffski, Oliver ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b SANOFI PASTEUR   (France)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia; Cost effectiveness analysis; Dynamic transmission model; Genital warts; Human papillomavirus; Quadrivalent HPV vaccine

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ARTICLE; CANCER SCREENING; CHILD; COHORT ANALYSIS; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DYNAMIC TRANSMISSION MODEL; FEMALE; GERMANY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MALE; MORBIDITY; PRIORITY JOURNAL; SCHOOL CHILD; SENSITIVITY ANALYSIS; STATISTICAL MODEL; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

EID: 84971219456     PISSN: None     EISSN: 21911991     Source Type: Journal    
DOI: 10.1186/2191-1991-2-19     Document Type: Article

References (44)

1. Baseman JG, Koutsky LA: The epidemiology of human papillomavirus infections. J Clin Virol 2005, 32(Suppl 1):S16-S24.
2. Walboomers JM, Meijer CJ, Steenbergen RD, van Duin M, Helmerhorst TJ, Snijders PJ: Human papillomavirus and the development of cervical cancer: concept of carcinogenesis. Ned Tijdschr Geneeskd 2000, 144:1671-1674.
3. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM: Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:1157-1164.
4. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121:621-632.
5. von Krogh G: Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001, 11:598-603. quiz 604.
6. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S: Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009, 124:1626-1636.
7. Kreimer AR, Clifford GM, Boyle P, Franceschi S: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005, 14:467-475.
8. Palefsky JM: Human papillomavirus-related disease in men: not just a women's issue. J Adolesc Health 2010, 46:S12-S19.
9. Cervix. http://www.rki.de/cln_160/nn_1219822/EN/Content/Health__Reporting/Broschuere/Krebslokalisationen__tabelle__gesamt.html. Accessed on 26 October 2011.
10. Sroczynski G, Schnell-Inderst P, Muhlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry KU, et al: Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany. GMS Health Technology Assessment 2010, 6:1-13.
11. Kraut AA, Schink T, Schulze-Rath R, Mikolajczyk RT, Garbe E: Incidence of anogenital warts in Germany: a population-based cohort study. BMC Infect Dis 2010, 10:360.
12. Schenck U, von Karsa L: Cervical cancer screening in Germany. Eur J Cancer 2000, 36:2221-2226.
13. Robert Koch-Institut: Mitteilung der Ständigen Impfkommission (STIKO) in Epidemiologisches Bulletin. 2007, 12:97-103.
14. Gardasil summary of product characteristics. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human_med_000805.jsp&mid=WC0b01ac058001d124. Accessed on 23 January 2011.
15. Cervarix summary of product characteristics. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000721/human_med_000694.jsp&mid=WC0b01ac058001d124. Accessed on 26 October 2011.
16. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, et al: Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011, 364:401-411.
17. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, et al: HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011, 365:1576-1585.
18. Hillemanns P, Petry KU, Largeron N, McAllister R, Tolley K, Busch K: Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany. J Pub Health 2009, 17:77-86.
19. Dasbach EJ, Largeron N, Elbasha EH: Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model. Expert Rev Pharmacoeconomics Outcomes Res 2008, 8:491-500.
20. Dasbach EJ, Insinga RP, Elbasha EH: The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 2008, 115:947-956.
21. Elbasha EH, Dasbach EJ, Insinga RP: Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007, 13:28-41.
22. Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM: Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 2007, 26:128-139.
23. Elbasha EH, Dasbach EJ, Insinga RP: A multi-type HPV transmission model. Bull Math Biol 2008, 70:2126-2176.
24. Federal joint committee guidelines for early diagnosis of cancer. http://www.g-ba.de/informationen/richtlinien/17/. Accessed on 1 May 2010.
25. Beasley M, Williams SG, Pickles T: Expanded risk groups help determine which prostate radiotherapy sub-group may benefit from adjuvant androgen deprivation therapy. Radiat Oncol 2008, 3:8.
26. National survey of sexual attitudes and lifestyles II, 2000-2001. http://dx.doi.org/10.5255/UKDA-SN-5223-1. Accessed on 23 January 2012.
27. Kerek-Bodden H, Altenhofen L, Brenner G: Abschlussbericht. Durchführung einer versichertenbezogenen Untersuchung zur Inanspruchnahme der Früherkennung auf Zervixkarzinom in den Jahren 2002, 2003 und 2004 auf der Basis von Abrechnungsdaten, Zentralinstitut für die kassenärztliche. Berlin: Versorgung in der Bundesrepublik Deutschland; 2009.
28. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, et al: Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007, 369:1693-1702.
29. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE: Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008, 14:244-251.
30. Robert Koch-Institut: Gesellschaft der epidemiologischen Krebsregister (Hrsg.). Ausgabe, RKI, Berlin: Krebs in Deutschland 2005/2006. Häufigkeiten und Trends. 7; 2010.
31. Petry KU, Breugelmans JG, Benard S, Lamure E, Littlewood KJ, Hillemanns P: Cost of screening and treatment of cervical dyskaryosis in Germany. Eur J Gynaecol Oncol 2008, 29:345-349.
32. Population Based Cancer Registry Bavaria. [http://www.ekr.med.uni-erlangen.de/]: Accessed on 1 May 2010.
33. Myers E, Green S, Lipkus I: Patient preferences for health states related to HPV infection: visual analogue scales vs. time trade-off elicitation. In Proceedings of the 21st International Papillomavirus Conference. Mexico City; 2004.
34. Hinzl A, Klaiberg A, Brähler E, König HH: Quality of life questionnaire EQ - 5D: modelling and reference values for the general population [Der Lebensqualitätsfragebogen EQ - 5D: Modelle undNormwerte für die Allgemeinbevölkerung]. PsychotherPsych Med 2006, 56:42-48.
35. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen: General methods for the assessment of the relation of benefits to costs Version 1.0. Available at: https://www.iqwig.de/download/General_Methods_for_the_Assessment_of_the_Relation_of_Benefits_to_Costs.pdf. Accessed May 1, 2010.
36. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand H, Fairley CK: Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011, 11:39-44.
37. Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK: The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011, 87:544-547.
38. Oliphant J, Perkins N: Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services. N Z Med J 2011, 124:51-58.
39. Gross MS, Andres R, Soren K: Human papillomavirus (HPV) vaccination in adolescent girls - have we seen a difference? J Pediatr Adolesc Gynecol 2010, 23:e70-e71.
40. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM: Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011, 377:2085-2092.
41. Jit M, Chapman R, Hughes O, Choi YH: Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011, 343:d5775-d5775.
42. Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, et al: A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009, 2:868-878.
43. Sinha P, Logan HL, Mendenhall WM: Human papillomavirus, smoking, and head and neck cancer. Am J Otolaryngol 2012, 33:130-136.
44. Sudhoff HH, Schwarze HP, Winder D, Steinstraesser L, Gorner M, Stanley M, Goon PK: Evidence for a causal association for HPV in head and neck cancers. Eur Arch Otorhinolaryngol 2011, 268:1541-1547.